Drug Trial Radar · NCT06926660
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
492
Actual
Start
Jul 18, 2025
Primary completion
Aug 14, 2026
Study completion Aug 14, 2026
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Apr 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication for kidney disease called SGLT2 inhibitor within 1 month before the study or have certain health conditions cannot take part in this study. The purpose of this study is to find out whether a medicine called vicadrostat, used in combination with another medicine called empagliflozin, works in people with chronic kidney disease. In this study, participants are randomly assigned to one of two groups. Participants have an equal chance of being assigned to either group. In one group, participants take the 2 study medicines, vicadrostat and empagliflozin, every day for 3 months. In the other group, participants take placebo and empagliflozin for the first 1.5 months, and then they take vicadrostat and empagliflozin together for the next 1.5 months. The study medicines are taken orally as tablets. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants are in the study for about 4.5 months. During this time, they visit the study site multiple times. Doctors regularly test kidney function by measuring specific proteins in the blood and urine. The results are compared between the two groups to see whether there are differences between starting the study medicines at the same time or one after the other. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Chronic Kidney Disease
Interventions
VicadrostatDrug
Vicadrostat
EmpagliflozinDrug
Empagliflozin
Placebo matching vicadrostatDrug
Placebo matching vicadrostat
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute change in estimated glomerular filtration rate (eGFR) (mL/min/1.73m2) from baseline to Week 14 and week 16Time frame: At baseline, up to week 16
Locations
157 sites in 24 countries. Site status is shown where the registry gives one.
Apogee Clinical Research
Huntsville, Alabama
Orange County Clinical Trials
Anaheim, California
North America Research Institute
San Dimas, California
Valiance Clinical Research-Tarzana-68237
Tarzana, California
Amicis Research Center - Valencia
Valencia, California
Focus Clinical Research
West Hills, California
Clinical Research of Brandon LLC
Brandon, Florida
Hillcrest Medical Research
DeLand, Florida
Encore Medical Research
Hollywood, Florida
Finlay Medical Research Corp
Miami, Florida
Total Research Group, LLC
Miami, Florida
San Marcus Research Clinic, Inc.
Miami Lakes, Florida
West Orange Endocrinology, PA
Ocoee, Florida
Florida Kidney Physicians - Riverview/Brandon
Riverview, Florida
Masters of Clinical Research, Inc
Augusta, Georgia
Boise Kidney and Hypertension, PLLC
Boise, Idaho
Research by Design, LLC
Chicago, Illinois
Nephrology Associates of Northern Illinois and Indiana - Oak Brook
Hinsdale, Illinois
Nephrology Associates of Northern Illinois and Indiana - Fort Wayne
Fort Wayne, Indiana
Kansas Nephrology Research Institute, LLC
Wichita, Kansas
Northwest Louisiana Nephrology
Shreveport, Louisiana
Aa Mrc Llc
Flint, Michigan
Michigan Kidney Consultants
Pontiac, Michigan
Elixia MNA, LLC
City of Saint Peters, Missouri
Healor Primary Care
Las Vegas, Nevada
Endocrine Associates of Long Island
Smithtown, New York
Durham Nephrology Associates
Durham, North Carolina
Lucas Research, Inc.
Morehead City, North Carolina
Brookview Hills Research Associates LLC
Winston-Salem, North Carolina
Heritage Valley Medical Group
Beaver, Pennsylvania
Southeast Renal Research Institute
Chattanooga, Tennessee
Arlington Nephrology
Arlington, Texas
Endocrine Associates
Houston, Texas
Clinical Advancement Center, PLLC
San Antonio, Texas
Javara Inc.-Stephenville-68996
Stephenville, Texas
Utah Kidney Research Institute
Salt Lake City, Utah
Tidewater Physicians Multispecialty Group
Newport News, Virginia
IDIM - Instituto de Diagnostico e Investigaciones Metabolicas
Buenos Aires, Argentina
CEDIC - Centro de Investigacion Clinica
CABA, Argentina
Mautalen- Salud e Investigacion
CABA, Argentina
Showing 40 of 157 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.